Laboratory Corporati

LH
Real-time BATS EXCHANGE - 02/20 01:43:30 pm
189.5USD
-0.09%
Income Statement Evolution
Annual Income Statement Data
Actuals in M $ Estimates in M $
Fiscal Period December 2019 2020 (e)
Sales 11 555 12 088
EBITDA 2 045 2 135
Operating profit (EBIT) 1 711 1 781
Pre-Tax Profit (EBT) 1 105 1 303
Net income 824 948
P/E ratio 20,3x 19,6x
EPS ( $ ) 8,35 9,69
Dividend per Share (  ) - -
Yield - -
Reference price ( $ ) 169,170 189,900
Announcement Date 02/13/2020
11:57am
-
Finances - Leverage
Actuals in M $ Estimates in M $
Fiscal Period December 2019 2020 (e)
Debt 5 967 5 464
Finance - -
Operating income (EBITDA) 2 045 2 135
Leverage
(Debt/EBITDA)
2,92x 2,56x
Capital Expenditure 400 430
Free Cash Flow (FCF) 1 045 1 098
Book Value Per Share (BVPS) ( $ ) 77,8 79,7
Cash Flow per Share ( $ ) 14,7 15,1
Announcement Date 02/13/2020
11:57am
-
Balance Sheet Analysis
Financial Ratios
Size 2020e 2021e
Capitalization 18 458 M $ -
Entreprise Value (EV) 23 922 M $ 23 184 M $
Valuation 2020e 2021e
P/E ratio (Price / EPS) 19,6x 17,8x
Capitalization / Revenue 1,53x 1,48x
EV / Revenue 1,98x 1,91x
EV / EBITDA 11,2x 10,7x
Yield (DPS / Price) - -
Price to book (Price / BVPS) 2,38x 2,08x
Profitability 2020e 2021e
Operating Margin (EBIT / Sales) 14,7% 14,8%
Operating Leverage (Delta EBIT / Delta Sales) 0,89x 1,13x
Net Margin (Net Profit / Revenue) 7,84% 8,30%
ROA (Net Profit / Asset) 6,40% 6,70%
ROE (Net Profit / Equities) 14,7% 14,6%
Rate of Dividend - -
Balance Sheet Analysis 2020e 2021e
CAPEX / Sales   3,56% 3,54%
Cash Flow / Sales 12,2% 13,0%
Capital Intensity (Assets / Sales) 1,23x 1,24x
Financial Leverage (Net Debt / EBITDA) 2,56x 2,12x
Price Earning Ratio
BNA & Dividende